Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 5, 2006, Pages 522-530

  Hukkanen, Janne ^a   Jacob III, Peyton ^a   Benowitz, Neal L ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; CYTOCHROME P450 2A6; DEUTERIUM; NICOTINE; WATER;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; DIZZINESS; ENZYME METABOLISM; EXCRETION; FEMALE; GRAPEFRUIT JUICE; HEADACHE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIVER METABOLISM; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; URINE LEVEL; VOLUNTEER; VOMITING;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BEVERAGES; CITRUS PARADISI; COTININE; DEUTERIUM; FEMALE; GANGLIONIC STIMULANTS; GLUCURONIDES; HALF-LIFE; HUMANS; KIDNEY; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NICOTINE;

EID: 33751100397     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.08.006     Document Type: Article

References (58)

1. Dresser G.K., Spence J.D., and Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38 (2000) 41-57
2. Dresser G.K., and Bailey D.G. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 33 Suppl 2 (2003) 10-16
3. Dahan A., and Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability-mechanism, extent and relevance. Eur J Clin Nutr 58 (2004) 1-9
4. Paine M.F., Criss A.B., and Watkins P.B. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther 312 (2005) 1151-1160
5. Huang S.M., Hall S.D., Watkins P., Love L.A., Serabjit-Singh C., Betz J.M., et al. Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther 75 (2004) 1-12
6. Kakar S.M., Paine M.F., Stewart P.W., and Watkins P.B. 6′7′-Dihydroxybergamottin contributes to the grapefruit juice effect. Clin Pharmacol Ther 75 (2004) 569-579
7. Pelkonen O., Rautio A., Raunio H., and Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology 144 (2000) 139-147
8. Merkel U., Sigusch H., and Hoffmann A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol 46 (1994) 175-177
9. Runkel M., Bourian M., Tegtmeier M., and Legrum W. The character of inhibition of the metabolism of 1,2-benzopyrone (coumarin) by grapefruit juice in human. Eur J Clin Pharmacol 53 (1997) 265-269
10. Bourian M., Runkel M., Krisp A., Tegtmeier M., Freudenstein J., and Legrum W. Naringenin and interindividual variability in interaction of coumarin with grapefruit juice. Exp Toxicol Pathol 51 (1999) 289-293
11. Tassaneeyakul W., Guo L.Q., Fukuda K., Ohta T., and Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 378 (2000) 356-363
12. He K., Iyer K.R., Hayes R.N., Sinz M.W., Woolf T.F., and Hollenberg P.F. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11 (1998) 252-259
13. Dresser G.K., Bailey D.G., Leake B.F., Schwarz U.I., Dawson P.A., Freeman D.J., et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71 (2002) 11-20
14. Lee Y.S., Lorenzo B.J., Koufis T., and Reidenberg M.M. Grapefruit juice and its flavonoids inhibit 11 beta-hydroxysteroid dehydrogenase. Clin Pharmacol Ther 59 (1996) 62-71
15. Hukkanen J., Jacob III P., and Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57 (2005) 79-115
16. Benowitz N.L., Jacob III P., Fong I., and Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 268 (1994) 296-303
17. Benowitz N.L., and Jacob III P. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 56 (1994) 483-493
18. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24 (1996) 1212-1217
19. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277 (1996) 1010-1015
20. Jacob III P., Yu L., Wilson M., and Benowitz N.L. Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. Biol Mass Spectrom 20 (1991) 247-252
21. Dempsey D., Tutka P., Jacob III P., Allen F., Schoedel K., Tyndale R.F., et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76 (2004) 64-72
22. Koskela S., Hakkola J., Hukkanen J., Pelkonen O., Sorri M., Saranen A., et al. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 57 (1999) 1407-1413
23. Lindell M., Karlsson M.O., Lennernas H., Pahlman L., and Lang M.A. Variable expression of CYP and Pgp genes in the human small intestine. Eur J Clin Invest 33 (2003) 493-499
24. Lilja J.J., Kivisto K.T., and Neuvonen P.J. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 66 (1999) 118-127
25. Lilja J.J., Kivisto K.T., Backman J.T., and Neuvonen P.J. Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol 56 (2000) 411-415
26. Veronese M.L., Gillen L.P., Burke J.P., Dorval E.P., Hauck W.W., Pequignot E., et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 43 (2003) 831-839
27. Vandel S., Netillard C., Perault M.C., and Bel A.M. Plasma levels of clozapine and desmethylclozapine are unaffected by concomitant ingestion of grapefruit juice. Eur J Clin Pharmacol 56 (2000) 347-348
28. Ozdemir V., Kalow W., Okey A.B., Lam M.S., Albers L.J., Reist C., et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 21 (2001) 603-607
29. Ozdemir V., Kalow W., Posner P., Collins E.J., Kennedy J.L., Tang B.K., et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol 21 (2001) 398-407
30. Lane H.Y., Jann M.W., Chang Y.C., Chiu C.C., Huang M.C., Lee S.H., et al. Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. J Clin Psychiatry 62 (2001) 812-817
31. Lane H.Y., Chiu C.C., Kazmi Y., Desai H., Lam Y.W., Jann M.W., et al. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo. Drug Metabol Drug Interact 18 (2001) 263-278
32. Fuhr U., Maier A., Keller A., Steinijans V.W., Sauter R., and Staib A.H. Lacking effect of grapefruit juice on theophylline pharmacokinetics. Int J Clin Pharmacol Ther 33 (1995) 311-314
33. Gupta M.C., Garg S.K., Badyal D., Malhotra S., and Bhargava V.K. Effect of grapefruit juice on the pharmacokinetics of theophylline in healthy male volunteers. Methods Find Exp Clin Pharmacol 21 (1999) 679-682
34. Fuhr U., Klittich K., and Staib A.H. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 35 (1993) 431-436
35. Maish W.A., Hampton E.M., Whitsett T.L., Shepard J.D., and Lovallo W.R. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. Pharmacotherapy 16 (1996) 1046-1052
36. Damkier P., Hansen L.L., and Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 48 (1999) 829-838
37. Kumar N., Garg S.K., and Prabhakar S. Lack of pharmacokinetic interaction between grapefruit juice and phenytoin in healthy male volunteers and epileptic patients. Methods Find Exp Clin Pharmacol 21 (1999) 629-632
38. Sullivan D.M., Ford M.A., and Boyden T.W. Grapefruit juice and the response to warfarin. Am J Health Syst Pharm 55 (1998) 1581-1583
39. Uno T., Yasui-Furukori N., Takahata T., Sugawara K., and Tateishi T. Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes. J Clin Pharmacol 45 (2005) 690-694
40. Tassaneeyakul W., Vannaprasaht S., and Yamazoe Y. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br J Clin Pharmacol 49 (2000) 139-144
41. Ducharme J., Abdullah S., and Wainer I.W. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 678 (1996) 113-128
42. Di Marco M.P., Edwards D.J., Wainer I.W., and Ducharme M.P. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 71 (2002) 1149-1160
43. Lucas D., Ferrara R., Gonzalez E., Bodenez P., Albores A., Manno M., et al. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 9 (1999) 377-388
44. Lin H.L., Kent U.M., and Hollenberg P.F. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 313 (2005) 154-164
45. Benowitz N.L., and Jacob III P. Nicotine renal excretion rate influences nicotine intake during cigarette smoking. J Pharmacol Exp Ther 234 (1985) 153-155
46. Trinchieri A., Lizzano R., Bernardini P., Nicola M., Pozzoni F., Romano A.L., et al. Effect of acute load of grapefruit juice on urinary excretion of citrate and urinary risk factors for renal stone formation. Dig Liver Dis 34 Suppl 2 (2002) S160-S163
47. Goldfarb D.S., and Asplin J.R. Effect of grapefruit juice on urinary lithogenicity. J Urol 166 (2001) 263-267
48. Honow R., Laube N., Schneider A., Kessler T., and Hesse A. Influence of grapefruit-, orange- and apple-juice consumption on urinary variables and risk of crystallization. Br J Nutr 90 (2003) 295-300
49. Embil K., Litwiller D.C., Lepore R.A., Field F.P., and Torosian G. Effect of orange juice consumption on urinary pH. Am J Hosp Pharm 33 (1976) 1294-1297
50. Takami K., Saito H., Okuda M., Takano M., and Inui K.I. Distinct characteristics of transcellular transport between nicotine and tetraethylammonium in LLC-PK1 cells. J Pharmacol Exp Ther 286 (1998) 676-680
51. Bendayan R., Sullivan J.T., Shaw C., Frecker R.C., and Sellers E.M. Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans. Eur J Clin Pharmacol 38 (1990) 165-169
52. Zevin S., Jacob III P., and Benowitz N.L. Nicotine-mecamylamine interactions. Clin Pharmacol Ther 68 (2000) 58-66
53. Zevin S., Schaner M.E., and Giacomini K.M. Nicotine transport in a human choriocarcinoma cell line (JAR). J Pharm Sci 87 (1998) 702-706
54. Wu X., George R.L., Huang W., Wang H., Conway S.J., Leibach F.H., et al. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta 1466 (2000) 315-327
55. Urakami Y., Akazawa M., Saito H., Okuda M., and Inui K. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 13 (2002) 1703-1710
56. Yabuuchi H., Tamai I., Nezu J., Sakamoto K., Oku A., Shimane M., et al. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther 289 (1999) 768-773
57. Urakami Y., Okuda M., Masuda S., Saito H., and Inui K.I. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 287 (1998) 800-805
58. Fukada A., Saito H., and Inui K. Transport mechanisms of nicotine across the human intestinal epithelial cell line Caco-2. J Pharmacol Exp Ther 302 (2002) 532-538